PCM
MGX icon

Prelude Capital Management’s Metagenomi Therapeutics MGX Stock Holding History

Prelude Capital Management’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,556
Closed -$34.8K – 1439
2025
Q1 		$34.8K Sell
25,556
-10,486
-29% -$25K ﹤0.01% 1107
2024
Q4 		$130K Buy
36,042
+21,968
+156% +$53K 0.01% 1067
2024
Q3 		$30.5K Buy
+14,074
New +$48.8K ﹤0.01% 1230

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's MGX Position: Q2 2025 in Review

Prelude Capital Management sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 25,556 shares — an estimated $34.8K sold.

Prelude Capital Management first reported a position in MGX in Q3 2024 and held it in 3 quarters. The position peaked at $130K in Q4 2024. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

  • Prelude Capital Management reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Prelude Capital Management sold 25,556 Metagenomi Therapeutics shares in Q2 2025, an estimated $34.8K.
  • Prelude Capital Management first reported a position in Metagenomi Therapeutics in Q3 2024 and held it in 3 quarters.
  • Prelude Capital Management's Metagenomi Therapeutics position peaked at $130K in Q4 2024.
  • 69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.